Gemzar, Cisp, Sunitinib Urothelial Ca

• Status: Completed
• Trial end date: 2012-08-01

Summary

The primary objective of this nonrandomized Phase II study is to evaluate the objective response rate (ORR, CR+PR) in patients with advanced/metastatic UC treated with the combination of gemcitabine, cisplatin, and sunitinib.

• Phase: Phase 2

Details

• Lead Sponsor: US Oncology Research
• Collaborator: Pfizer
• Treatments: Cisplatin; Gemcitabine; Sunitinib